Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 24, 2023 - Issue 5-6
Submit an article Journal homepage
1,560
Views
5
CrossRef citations to date
0
Altmetric
Clinical Trial

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Jeremy M. Shefner1 Barrow Neurological Institute, University of Arizona, and Creighton University, Phoenix, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5067-5602View further author information
ORCID Icon,
Ammar Al-Chalabi2 King’s College London, London, UKORCID Iconhttps://orcid.org/0000-0002-4924-7712View further author information
ORCID Icon,
Jinsy A. Andrews3 The Neurological Institute of New York, Columbia University Irving Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3474-7140View further author information
ORCID Icon,
Adriano Chio4 Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, ItalyORCID Iconhttps://orcid.org/0000-0001-9579-5341View further author information
ORCID Icon,
Mamede De Carvalho5 Department of Neurosciences of Centro Hospitalar Universitário Lisboa-Norte, Faculty of Medicine, Centro de Estudos Egas Moniz, Institute of Molecular Medicine, Universidade de Lisboa, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0001-7556-0158View further author information
ORCID Icon,
Bettina M. Cockroft6 Sangamo Therapeutics, Inc, Brisbane, CA, USAView further author information
,
Philippe Corcia7 Centre de Réference SLA, CHU Bretonneau, Tours, FranceORCID Iconhttps://orcid.org/0000-0002-1625-8845View further author information
ORCID Icon,
Philippe Couratier8 Neurology Department, LS Centre CHU Dupuytren, Limoges, FranceORCID Iconhttps://orcid.org/0000-0001-9562-856XView further author information
ORCID Icon,
Merit E. Cudkowicz9 Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0002-7075-1681View further author information
ORCID Icon,
Angela Genge10 Montreal Neurological Institute, Montreal, QC, CanadaORCID Iconhttps://orcid.org/0000-0001-5587-9946View further author information
ORCID Icon,
Orla Hardiman11 Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, IrelandORCID Iconhttps://orcid.org/0000-0003-2610-1291View further author information
ORCID Icon,
Terry Heiman-Patterson12 Neurology Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-9910-1041View further author information
ORCID Icon,
Robert D. Henderson13 UQ Centre for Clinical Research, The University of Queensland, Brisbane, AustraliaORCID Iconhttps://orcid.org/0000-0002-2820-8183View further author information
ORCID Icon,
Caroline Ingre14 Department of Clinical Neuroscience, Karolinska Institute, Stockholm, SwedenORCID Iconhttps://orcid.org/0000-0001-5327-7204View further author information
ORCID Icon,
Carlayne E. Jackson15 University of Texas Health Science Center at San Antonio, San Antonio, TX, USAORCID Iconhttps://orcid.org/0000-0002-9368-395XView further author information
ORCID Icon,
Wendy Johnston16 University of Alberta, Edmonton, AB, CanadaView further author information
,
Noah Lechtzin17 Johns Hopkins University School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-9088-8749View further author information
ORCID Icon,
Albert Ludolph18 UULM Clinic of Neurology, Ulm University, Ulm, GermanyORCID Iconhttps://orcid.org/0000-0002-5401-0904View further author information
ORCID Icon,
Nicholas J. Maragakis19 Johns Hopkins ALS Clinical Trials Unit, Johns Hopkins University, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-7311-9614View further author information
ORCID Icon,
Timothy M. Miller20 Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0002-3424-5511View further author information
ORCID Icon,
Jesus S. Mora Pardina21 ALS Unit, Hospital Universitario San Rafael, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-6633-5354View further author information
ORCID Icon,
Susanne Petri22 Department of Neurology, Hannover Medical School, Hannover, GermanyORCID Iconhttps://orcid.org/0000-0002-9783-8584View further author information
ORCID Icon,
Zachary Simmons23 Penn State Health Milton S Hershey Medical Center, Hershey, PA, USAORCID Iconhttps://orcid.org/0000-0001-8574-5332View further author information
ORCID Icon,
Leonard H. Van Den Berg24 Department of Neurology, UMC Utrecht Brain Center, Netherlands ALS Centre, University Medical Center Utrecht, Utrecht, NetherlandsORCID Iconhttps://orcid.org/0000-0002-5203-9674View further author information
ORCID Icon,
Lorne Zinman25 Sunnybrook Health Sciences Centre, Toronto, ON, Canada, andORCID Iconhttps://orcid.org/0000-0002-8096-8366View further author information
ORCID Icon,
Stuart Kupfer26 Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-5469-1287View further author information
ORCID Icon,
Fady I. Malik26 Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-5597-5759View further author information
ORCID Icon,
Lisa Meng26 Cytokinetics, Incorporated, South San Francisco, CA, USAView further author information
,
Tyrell J. Simkins26 Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-6063-174XView further author information
ORCID Icon,
Jenny Wei26 Cytokinetics, Incorporated, South San Francisco, CA, USAView further author information
,
Andrew A. Wolff26 Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-9094-0359View further author information
ORCID Icon &
Stacy A. Rudnicki26 Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-3499-5208View further author information
ORCID Icon show all
Pages 523-534 | Received 05 Dec 2022, Accepted 15 May 2023, Published online: 30 May 2023

References

  • Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
  • Edaravone (MCI-186) ALS 19 Study Group Writing Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
  • Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31–9.
  • US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Amyotrophic lateral sclerosis: developing drugs for treatment. Guidance for industry. https://www.fda.gov/media/130964/download. Accessed August 3, 2022.
  • ClinicalTrials.gov. The PHOENIX trial: phase III trial of AMX0035 for amyotrophic lateral sclerosis treatment. NCT05021536. 2022. https://clinicaltrials.gov/ct2/show/NCT05021536
  • ClinicalTrials.gov. The HEALEY ALS platform trial. NCT04297683. 2022. https://clinicaltrials.gov/ct2/show/NCT04297683
  • Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57:729–34.
  • Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:287–99.
  • de Jongh AD, Braun N, Weber M, van Es MA, Masrori P, Veldink JH, et al. Characterising ALS disease progression according to El Escorial and Gold Coast criteria. J Neurol Neurosurg Psychiatry. 2022;93:865–70.
  • Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, Kollewe K, Paracka L, Dengler R, et al. Diagnostic criteria for amyotrophic lateral sclerosis: a multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol. 2019;130:307–14.
  • Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
  • Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.
  • Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:86–91.
  • Pinto S, de Carvalho M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol. 2019;10:109.
  • Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, et al. MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(3-4):304–10.
  • Chen YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded interim result is promising. Stat Med. 2004;23:1023–38.
  • Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18:1184–96.
  • Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med. 2011;30:3267–84.
  • van Eijk RPA, Bakers JNE, van Es MA, Eijkemans MJC, van den Berg LH. Implications of spirometric reference values for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:473–80.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.